Kornimate/medical-research-clean huggingface dataset:
revised capsular polishing and its impact on the positioning of the intraocular lens and visual quality following femtosecond laser-assisted cataract surgery

Conditions: Cataract

Summary: this study aims to investigate the impact of improved capsular polishing on the long-term stability of effective lens position (elp) and visual quality in patients following femtosecond laser-assisted cataract surgery combined with intraocular lens implantation. throughout the follow-up period, changes in elp were observed using oct to measure the central corneal posterior surface to the iol anterior surface. the contraction of the anterior capsule orifice was assessed through anterior segment photography, and its diameter and area were measured and analyzed using drawing software at each follow-up visit. additionally, the investigators analyzed the correlation between the degree of anterior capsule orifice contraction and elp, as well as examined whether aco formed and its degree, pco formation and its degree. objective examination using oqas ii was conducted to measure psf, mtf, osi, and sr of patients; high-order aberrations including astigmatism, trifolium, and spherical aberration were measured by opd-scan iii. furthermore, the investigators investigated the correlation between aco/pco degrees and visual quality.


Eligibility criteria:
inclusion criteria: 1. diagnosed with age-related cataract 2. patients seeking to reduce their reliance on corrective eyewear postoperative and exhibiting high expectations for optimal visual acuity at all distances - near, intermediate, and distant 3. anticipated postoperative astigmatism of ≤1.00d 4. pupil diameter in a darkened environment ranging from 3.0-5.5 mm 5. kappa angle ≤0.5 mm or less than half the diameter of the central refractive optical zone of the miol. exclusion criteria: 1. progressive and aggravated retinal diseases, such as diabetic retinopathy, macular degeneration, preretinal membrane, vitreous macular traction syndrome, stargardt disease, retinitis pigmentosa, etc., and serious optic nerve diseases 2. small eyeballs, ultra-high myopia, obvious pupil abnormalities, severe corneal lesions, severe irregular astigmatism, chronic uveitis, glaucoma, obvious abnormalities of lens capsule membrane and suspension ligament, major degree alternating strabismus and other ocular organic diseases and amblyopia 3. severe mental and psychological diseases 4. history of internal eye surgery 5. posterior capsule rupture or uneventful in-the-bag iol implantation

Keywords: visual acuity visual quality polishing femtosecond laser
the combined aerobic exercise and cognitive training (act) trial: the act trial

Conditions: Mild Cognitive Impairment

Summary: this multi-site clinical trial occurs at the university of minnesota and university of rochester. it tests the efficacy and additive/synergistic effects of an act intervention on cognition and relevant mechanisms (aerobic fitness, alzheimer's disease \[ad\] signature cortical thickness, and default mode network \[dmn\]) in older adults with amnestic mci (amci).

because almost all drug trials for alzheimer's disease (ad) have failed, developing non-pharmacological interventions with strong potential to prevent or delay the onset of ad in high-risk populations (e.g., those with mild cognitive impairment \[mci\]) is critically important. aerobic exercise and cognitive training are 2 promising interventions for preventing ad. aerobic exercise increases aerobic fitness, which in turn improves brain structure and function, while cognitive training improves selective neural function intensively. hence, combined aerobic exercise and cognitive training (act) may very well have an additive or synergistic effect on cognition by complementary strengthening of different neural functions. few studies have tested act's effects, and those studies have reported discrepant findings, largely due to varying act programs. the purpose of this single-blinded, 2×2 factorial phase ii randomized controlled trial (rct) is to test the efficacy and additive/synergistic effects of a 6-month combined cycling and speed of processing (sop) training intervention on cognition and relevant mechanisms (aerobic fitness, ad signature cortical thickness, and functional connectivity in the default mode network \[dmn\]) in older adults with amnestic mci (amci).

Eligibility criteria:
inclusion criteria: * a clinical diagnosis of mci * community-dwelling * age 65 years and older * english-speaking * adequate visual acuity * verified exercise safety by medical provider * stable on drugs affecting cognitive and psychological status * verified mri safety * capacity to consent exclusion criteria: * geriatric depression scale \< 5 * resting heart rate (hr) ≤50 due to arrhythmia or ≥100 beats/min * neurological (e.g., dementia, head trauma), psychiatric (e.g., bipolar, schizophrenia, or depression), or substance dependency (alcohol or chemical dependency) in the past 5 years that are the main contributor to mci * contraindications to exercise, e.g. unstable angina, recent surgery * new symptoms or diseases that have not been evaluated by a health care provider * current enrollment in another intervention study related to cognitive improvement (reduce confounding effects on outcomes) * abnormal mri findings

Keywords: alzheimer's disease exercise cognitive training imaging
prehabilitation for pad revascularization patients

Conditions: Peripheral Vascular Disease; Peripheral Artery Disease

Summary: patients undergoing elective revascularization of their peripheral artery disease will be randomized to a prehabilitation program or usual care prior to their scheduled procedure.

patients undergoing elective revascularization for their peripheral artery disease will be randomized to a "prehabilitation" program prior to their surgery or to usual care. the prehabilitation program is self-directed program designed to improve health and quality of life prior to surgery. the program is currently offered to general surgery patients; this study will examine the feasibility and acceptability of such a program in a different patient population.

Eligibility criteria:
inclusion criteria: * documented lower extremity pad * ability to walk at least 1 block * sedentary * medical clearance from the surgical team * competent to provide consent exclusion criteria: * life expectancy \< 6 months * co-morbidities which limit walking to a severe degree * signs of critical limb ischemia * recent or current enrollment in a formal exercise program * recent cardiovascular events including stroke, tia, severe valve disease, etc. * current substance abuse * psychiatric disorder which limits ability to participate in study procedures * non-english speaking
a phase 1/2 multicenter dose escalation and expansion study of nktr-214 in subjects with locally advanced or metastatic solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: this is a first in human, open-label, sequential dose escalation and expansion phase 1 study of nktr-214 in adult patients with locally advanced or metastatic solid tumors.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of a locally advanced or metastatic solid tumor. * received 1 or 2 prior lines of therapy. * life expectancy \>12 weeks. * eastern cooperative oncology group (ecog) performance status 0 to 1. * measurable disease per recist v1.1. * demonstrated adequate organ function within 14 days of treatment initiation. * subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior system anticancer therapy, radiotherapy or surgery. * women of childbearing potential must agree to use highly effective methods of birth control. * all participants must agree to use double barrier contraception during study participation and for at least 2 months after the last dose of study drug. * additional criteria may apply. exclusion criteria: * use of an investigational agent or an investigational device within 28 days before administration of first dose of nktr-214. * females who are pregnant or breastfeeding. * participants who have an active autoimmune disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic steroids or immunosuppressive agents. * active central nervous system (cns) metastases. * prior surgery or radiotherapy within 14 days of therapy. * participants who have had \< 28 days since the last chemotherapy, immunotherapy, biological therapy, or \< 14 days from approved tyrosine kinase inhibitor (tki) therapy (sunitinib, sorafenib, vemurafenib, dabrafenib, cobimetinib), or systemic or inhaled steroid therapy at doses greater than 10mg of prednisone or equivalent before administration of the first dose of study medication. * participants' inability to adhere to or tolerate protocol or study procedures. * additional criteria may apply.

Keywords: metastatic solid tumors locally advanced solid tumors
wellbutrin xl, major depressive disorder and breast cancer

Conditions: Breast Cancer; Major Depressive Disorder

Summary: * to evaluate the efficacy of bupropion extended release (wellbutrin xl™) in the treatment of major depressive disorder in women with breast cancer. * to evaluate the tolerability of bupropion extended-release (wellbutrin xl™) in these patients

this is research study for women diagnosed with breast cancer and major depression. women with breast cancer who are depressed may report greater pain, poorer quality of life and worse overall functioning than those without depression. the study will determine whether or not bupropion extended release (wellbutrin xltm) is useful in lessening the symptoms of depression in women with breast cancer. one reason for conducting this research with bupropion extended release (wellbutrin xltm) instead of another antidepressant is because bupropion has a lower likelihood of causing the side effects of weight gain, sexual dysfunction, and fatigue, which may be important for women with breast cancer and may even have a beneficial effect on these symptoms. bupropion extended release (wellbutrin xl™)is approved by the united states food and drug administration (fda) for the treatment of major depression.

Eligibility criteria:
inclusion criteria: * women aged 18 years or older * diagnosis of breast cancer, confirmed by histopathology; stages 0, i, ii, iiia, or iiib * clinical diagnosis of major depressive disorder (dsm-iv-tr) * hospital anxiety and depression scale (zigmond and snaith, 1983) depression subscale score of 11 or greater * montgomery asberg depression rating scale (madrs; montgomery and asberg, 1979) score of 25 or greater at screening and baseline visits * use of antidepressants in a previous episode of major depression or in the past for any other indication does not affect the patient's inclusion in this study. * during the current episode of major depressive disorder, as stated in the exclusion criteria, failure to respond to one or more adequate trials of an antidepressant will exclude the patient from the study since this is not a study of "treatment-resistant depression". * during the study, the patient may not use any other antidepressants. exclusion criteria: * presence of another current clinically significant axis i disorder like bipolar disorder, schizophrenia, or panic disorder * current (in past 6 months) comorbid active substance abuse or dependence * failure to respond to one or more adequate trials of an antidepressant in the current episode of mdd * a reduction in madrs score of 20% or greater from screening to baseline visit * clinically significant laboratory abnormalities that in the judgment of the investigator would increase risk of adverse effects with bupropion * pregnant or lactating women * history of an eating disorder, seizures, head injury, or other intracranial pathology because these conditions are usually contraindications to the use of bupropion xl * previous allergy or intolerance to bupropion * patients judged to be at significant suicidal risk

Keywords: breast cancer major depressive disorder
telediet study: the impact of dietary education and counseling with a smartphone application on secondary prevention of coronary artery disease

Conditions: Coronary Artery Disease

Summary: digital cardiology is gaining power in the field of preventive cardiology recently, and several trials have already shown good results of dietary therapy with digital cardiology. however, there has been no reports that showed effect of dietary counseling through digital cardiology for secondary prevention of coronary artery disease. telediet study investigates the impact of dietary therapy with a smartphone application on the content of meals and metabolic parameters for patients with coronary artery disease.


Eligibility criteria:
inclusion criteria: 1. owning a smartphone and able to use it 2. written informed consent obtained 3. starting cardiac rehabilitation 4. coronary artery disease exclusion criteria: 1. special diet due to other reasons (eg. renal diet, pancreatic insufficiency diet) 2. age \<18 years old 3. pregnancy

Keywords: coronary artery disease secondary prevention diet therapy
evaluation of soft tissue response to titanium healing abutments treated by erbium: yag laser or plasma spray

Conditions: Peri-implant Mucositis

Summary: the attachment of peri implant soft tissue to the implant serves as a biological seal that can prevent the development of inflammatory peri-implant diseases. presence of contaminants has been suggested to be associated with tissue damaging inflammation and titanium wear microparticles were demonstrated to activate osteoclastic action. er: yag laser has been extensively investigated clinically for applications for treating periimplantitis either independently or in combination with other techniques, showing favorable outcomes. plasma spray treatment can decontaminate surfaces without modifying their topography. it is also able to increase the surface energy by obtaining more hydrophilic surfaces, which may increase the capacity of the titanium oxide layer to interact with cells and proteins of surrounding tissue improving cell adhesion to the treated surface.

this study was conducted on 24 patients seeking implant placement. a total number of 33 healing abutments were included in this study, they were divided into 3 groups. group 1 (laser group): 8 patients in this group received 11 healing abutments treated with er:yag laser, group 2 (plasma group): 8 patients in this group received 11 healing abutments treated with plasma sprayand group 3 (control group): 8 patients in this group received 11 healing abutments with no surface treatment.three months after implants placement, patients included in the study were randomly assigned to one of the three study groups, second stage surgery was performed and patients received healing abutments without surface treatment in control group, surface treatment was performed in plasma and laser groups. after two weeks, clinical assessment was done using pi and gi before taking biopsies from peri-implant soft tissue for histological assessment. h\&e stain was used for measuring inflammatory cells count and masson's trichrome stains for measuring collagen fibers area fraction. analysis of the abutments surface was done using sem.

Eligibility criteria:
inclusion criteria: * male and female patients with age range from 20 to 45 years old. * patients need placement of fixed implant-supported prosthesis in maxillary arch. * patients who are medically free from any systemic diseases as evidenced by the health questionnaire, using modified cornell medical index (pendleton et al., 2004). * patients with good oral hygiene (plaque index and bleeding on probing less than or equal to grade 1). * absence of any local conditions affecting bone-implant osseointegration (e.g., infection and poor bone density). * the presence of sufficient bone width and height that permit the placement of implant with minimum diameter 3.5 mm and 8.5 mm length. exclusion criteria: * presence of acute infections. * smokers. * pregnancy and lactation. * patients with a history of bisphosphonates therapy.

Keywords: healing abutment plasma spray er: yag laser
what is the effective pulmonary physiotherapy method in critically care patients?

Conditions: Atelectasis

Summary: effects of the high frequent chest wall oscillation technique applied on the patients who were intubated in intensive care unit were investigated. a total of 30 patients who were intubated and under the mechanical ventilator supplied, were included in the study. while the control group (n=15) received routine pulmonary rehabilitation technique, the study group (n=15) was administered high frequency chest wall oscillation for 72 hours as 4 times of 15-minute intervals, in addition to the pulmonary rehabilitation technique. patients 'apache-ii scores, dry sputum weight, lung collapse index and blood gas values were measured at the hours 24th, 48th and 72nd, and endotracheal aspirate culture was studied at initial and 72nd. in addition, patient outcomes were evaluated at the end of the first week.


Eligibility criteria:
inclusion criteria: * aged over 18 years * patients with more than three days intubated, in critical care unit of mengücekgazi training and research hospital exclusion criteria: * patients with rib fracture * acute hemorrhage * unstable intracranial pressure * existence of chest drainage tube and those have history of spinal surgery, * skin infection in the back and chest area and subcutaneous emphysema

Keywords: pulmonary rehabilitation chest physiotherapy high frequency chest wall oscillation
intravenous acetaminophen and morphine versus intravenous morphine alone for acute pain in the emergency department

Conditions: Pain Management

Summary: in emergency medicine, acute pain is a common reason for consultation. it is recommended that patients in moderate to severe pain should receive a combination of intravenous acetaminophen and morphine. however, the data are sparse to support this strategy. thus, the purpose of our research is to test non-inferiority of iv morphine alone versus iv acetaminophen and morphine in a multicenter, randomized, controlled double blind trial in ed patients with moderate to severe acute pain.

this study is designed to assess whether iv morphine alone is non inferior to combination iv acetaminophen and morphine for the management of moderate to severe pain in the ed. numeric rating scale pain score will be compared between those who receive morphine alone and who will receive acetaminophen and morphine at 15, 30, 45 and 60 min post first injection.

Eligibility criteria:
inclusion criteria: * 18 years and older * moderate to severe acute pain, defined as a numeric rating scale score greater than or equal to 5. * conscious patient * clinical stability at the physician's discretion * patient able to talk and give a verbal assessment of his/her pain with the numerical verbal scale * out of guardianship and/or tutorship * affiliated to the social security plan. exclusion criteria: * pregnancy and breast-feeding * patient unable to give numeric rating scale scores * patient with a weight strictly less than 50kg. * acute pulmonary edema, acute respiratory failure * acute coronary syndrome or unbalanced ischemic heart disease in progress. * acute alcoholic intoxication. * patient who received morphine, or acetaminophen, or analgesic, or anti-inflammatory, for the current acute pain episode, within 8 hours prior to arrival at the emergencies * no possibility of having venous access * history of chronic pain during treatment. * allergy, intolerance or know contraindication to paracetamol or morphine or to an excipient. * renal or hepatic insufficiency. * association with buprenorphine, nalbuphine and pentazocine. * patient unable or unable to give written consent.

Keywords: morphine acetaminophen acute pain analgesics
the use of eeg in alzheimer's disease, with and without scopolamine - a pilot study

Conditions: AD

Summary: the objective of this study is to compare the electroencephalography (eeg) responses of three distinct groups of individuals to scopolamine: 1) a group of alzheimer dementia (ad) patients, 2) a group of individuals suffering from mild cognitive impairment (mci) and 3) a group of controls. the main purpose of this comparison is to discover ways to use these responses to distinguish between the group of ad patients and controls in order to develop a diagnostic tool for ad. the purpose of including the mci group is to investigate whether this diagnostic tool can predict which member of the mci group will develop ad later in life.


Eligibility criteria:
inclusion criteria: healthy subjects: * between 60-80 years of age. * volunteers will have to be in good general health as determined by standard physical examination. * normal electrocardiograph (ecg) mci subjects: * diagnosed with mci at the memory clinic at the landspitali university hospital using f 06,7 according to international classification of diseases (icd) - 10. * between 60-80 years of age. * subjects need to score between 2 and 3 on the global deterioration scale (gds). * normal ecg alzheimer's patients: * diagnosed with ad according to icd - 10 in follow up at the memory clinic at the landspitali university hospital. * between 60-80 years of age. * subjects need to score between 3-5 on the gds. * normal ecg * treated with reminyl® for the alzheimer disease. exclusion criteria: * smoking or any other use of tobacco. * taking neuroleptics or benzodiazepines (allowed to take oxazepam ad vesp). * neurological-, cardiovascular-, gastrointestinal- or genitourinary disorders of medical importance. * glaucoma or history of possibly raised intraocular pressure. * impaired liver- or kidney function. * hypersensitivity to scopolamine or any component in the formulation. * any indication of drug, alcohol or medicine abuse. * participation in another investigational study at the same time.

Keywords: scopolamine, ad, eeg, mci
examining digital health care delivery models through medicaid collaborative

Conditions: Hypertension; Diabetes Mellitus; Maternal Health

Summary: the purpose of this study is to examine the intervention effectiveness and dissemination of digital health care delivery models for improving selected health outcomes in the medicaid population.

the investigators will conduct a mixed method study that includes a controlled interrupted times series (cits) design to study hypertension (htn) and diabetes, a cohort to study pregnancy, and longitudinal patient and provider interviews to study experiences. this approach is appropriate when randomization is not desirable or feasible and is frequently utilized for evaluation of public health interventions (lopez bernal et al., 2018; hategeka et al., 2020).

Eligibility criteria:
inclusion criteria: * patient of one of four medically qualified health care centers and/or osf healthcare as defined by insurance type * insured by medicaid or dually eligible for medicare or medicaid * has one or more of the three following conditions: hypertension, diabetes mellitus, or pregnancy * able to read and understand english or read translated materials in language provided (e.g. spanish) * minors who are pregnant and less 18 years of age who are enrolled in the mic program exclusion criteria: * not enrolled in the mic program * no one will be excluded on basis of sex or race

Keywords: hypertension diabetes maternal health digital health